Welcome to our dedicated page for Spero Therapeuti SEC filings (Ticker: SPRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spero Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing treatments for rare diseases and multi-drug resistant bacterial infections. Form 8-K reports cover operating results, Regulation FD investor presentations, tebipenem HBr business updates, compensatory arrangements, board changes, and other material events.
Proxy materials describe director elections, annual meeting votes, executive compensation, board committees, and stock incentive plan matters. The filing record also identifies the company’s common stock, par value and exchange listing, and records governance and regulatory matters including the reported conclusion of a previously disclosed SEC investigation without a recommended enforcement action.
Spero Therapeutics (SPRO) reported a strong clinical milestone and narrower losses in the quarter ended June 30, 2025. The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy after a pre-specified interim analysis of 1,690 patients, and the company has shifted its R&D focus to tebipenem while suspending SPR720 oral development and discontinuing SPR206.
Financially, total revenues were $14.2 million for the quarter and $20.1 million for the six months, driven by related-party collaboration revenue and grant revenue. Net loss improved to $1.7 million for the quarter ($0.03 per share) and $15.6 million for six months ($0.28 per share), compared with larger losses a year earlier. Cash and cash equivalents were $31.2 million at June 30, 2025, down from $52.9 million at year-end, and the company used $21.7 million of cash in operations in the six months. The company received significant upfront and milestone payments from GSK (including a $66.0 million upfront payment) and reports committed BARDA funding of $65.6 million (with $61.1 million recognized to date). The company disclosed an SEC Wells Notice and ongoing cooperation with the staff, and regained Nasdaq bid-price compliance on June 12, 2025.
Spero Therapeutics announced it issued a press release reporting results for the third quarter ended June 30, 2025. The 8-K furnishes that press release as Exhibit 99.1, but the filing itself does not include the underlying financial figures in-line.
The company also furnished an investor presentation as Exhibit 99.2, which management intends to use in investor communications and is available on the company website. Both the press release and presentation are described as "furnished" and are not deemed "filed" for purposes of certain securities-law liabilities.
Spero Therapeutics’ Form 8-K details the voting results of its 12 June 2025 Annual Meeting. A quorum of 40,015,633 shares (71.57%) of the 55.9 million shares outstanding was present.
Board elections: Class II directors Frank E. Thomas, Patrick Vink M.D., and Esther Rajavelu were re-elected through 2028, each receiving roughly 25.7 million votes for and 0.4-2.9 million votes withheld; 13.8 million broker non-votes were recorded.
Auditor ratification: PricewaterhouseCoopers LLP was confirmed as independent auditor for FY 2025 with an overwhelming 39.8 million ‘for’ versus 175 k ‘against’.
Say-on-pay: Executive compensation received shareholder support—25.18 million ‘for’ (96.0%) against 0.64 million ‘against’.
Equity plan amendment: Shareholders approved increasing the 2017 Stock Incentive Plan by 3 million additional shares (22.97 million for / 3.15 million against). This authorizes extra equity that may dilute existing holders once issued but expands flexibility to attract and retain talent.
No financial performance data, earnings guidance, or major strategic transactions were disclosed; the filing is limited to governance and compensation matters.